Androgen Receptor Blockers: Uses, Types, and Side Effects

Androgen receptor blockers, commonly called antiandrogens, are drugs that prevent testosterone and its more potent derivative dihydrotestosterone from activating the androgen receptor, a protein that relays hormonal signals throughout the body. They occupy a central role in treating prostate cancer but have expanded into dermatology, endocrinology, and gender-affirming hormone therapy. Along with that broadened use come side effects that range from mild nuisances to serious cardiovascular and liver complications, depending on the drug, the dose, and how long it is taken.

How They Work

Androgens normally bind to the androgen receptor inside a cell, triggering a shape change that allows the receptor to enter the nucleus and switch on genes involved in growth and reproduction. Antiandrogens compete for the same binding pocket, but when they occupy it, they prevent the receptor from completing that shape change. Pure antiandrogens lock the receptor in a halfway state, keeping it stuck to a chaperone protein called hsp90 and unable to reach the nucleus at all.¹ In animal studies, when antiandrogens were given in place of dihydrotestosterone, essentially no receptor molecules made it into cell nuclei, compared with thousands when the natural hormone was present.²

The net effect is the same across drugs in this class: androgen-driven processes slow down or stop. But the hormonal ripple effects differ depending on whether the drug has a steroidal or nonsteroidal structure, a distinction that shapes both the benefits and the risks for the person taking it.

Steroidal Versus Nonsteroidal Types

Antiandrogens fall into two chemical families. Steroidal antiandrogens, such as cyproterone acetate, resemble the body’s own hormones closely enough that they also suppress the brain’s hormonal feedback loop. This means they lower circulating testosterone as a side effect of their structure, producing a near-castration hormonal profile that amplifies their antiandrogenic punch but also brings sexual side effects that closely mimic surgical castration.³ Cyproterone acetate was discovered accidentally during a chemical screen, gained an acetate group to boost potency, and became the first antiandrogen approved for prostate cancer in the late 1980s after a phase III trial showed it matched medical castration with diethylstilbestrol.⁴

Nonsteroidal antiandrogens took a different path. Because they do not mimic steroid hormones, they block androgen receptors in tissues without suppressing the brain’s feedback mechanism. The brain, sensing that androgen signaling in the hypothalamus is also blocked, actually ramps up testosterone production in the testes.³ That sounds counterproductive, and it would be if the drug were used alone. In prostate cancer, nonsteroidal antiandrogens are therefore paired with a GnRH agonist or antagonist that separately shuts down testicular production, creating what oncologists call combined androgen blockade.

Flutamide, approved by the FDA in 1989, was the first nonsteroidal antiandrogen. Bicalutamide followed in 1995 and nilutamide in 1996.⁴ These are now collectively called “first-generation” antiandrogens. They established the principle that blocking the receptor could control prostate cancer, but they did not completely shut down all androgen receptor activity, and cancers could eventually grow through them.⁵

Second-Generation Drugs and Their Impact on Prostate Cancer

The understanding that even castration-resistant tumors still depend on androgen receptor signaling led to the development of second-generation agents. Enzalutamide binds the receptor more tightly than earlier drugs and also blocks additional downstream steps, making it harder for the cancer to use the receptor as a growth signal. Its approval, along with abiraterone (which blocks androgen production rather than the receptor itself), represented proof that the receptor remains a worthwhile target even in late-stage disease. Both drugs extended survival in patients whose cancer had progressed despite chemotherapy.⁶

Combined androgen blockade, which pairs a GnRH analog with an antiandrogen to block both sources of androgens, was actually the first treatment shown in randomized, placebo-controlled trials to prolong life in metastatic prostate cancer, a milestone first published in 1982.⁷ Recent trials continue to refine the pairing: one multicenter study found that combining a GnRH agonist with bicalutamide produced longer progression-free survival than using a GnRH antagonist alone in advanced hormone-sensitive prostate cancer.⁸ Another study found that combining a GnRH antagonist with a nonsteroidal antiandrogen improved the time before PSA recurrence compared with combining a GnRH agonist with the same antiandrogen, suggesting the choice of backbone hormone-suppression drug matters too.⁹

Uses Beyond Cancer

Prostate cancer treatment drove the development of antiandrogens, but the same receptor-blocking mechanism turns out to be useful wherever androgen-driven conditions cause problems. Three areas now make up a significant share of antiandrogen prescribing.

Hair Loss and Skin Conditions

Female pattern hair loss is one of the most common reasons women receive oral antiandrogens like spironolactone or cyproterone acetate. A meta-analysis covering about 190 patients found that roughly 57% of women treated with oral spironolactone experienced improved hair loss, with the rate rising to about 66% when spironolactone was combined with other therapies.¹⁰ A separate study of 80 women treated with oral antiandrogens found that 44% had regrowth, another 44% stabilized, and only 12% continued losing hair, meaning about 88% could expect at least no further progression.¹¹

For polycystic ovary syndrome, where excess androgens drive hirsutism and acne, a systematic review and meta-analysis concluded that anti-androgens should be considered when oral contraceptives are contraindicated, poorly tolerated, or produce a suboptimal response after at least six months.¹² Quality-of-life studies in women with PCOS show marked improvement after antiandrogen treatment, particularly in psychological and emotional wellbeing.¹³

Gender-Affirming Hormone Therapy

Transgender women commonly take an antiandrogen alongside estradiol to suppress the effects of endogenous testosterone. A systematic review found that cyproterone acetate, leuprolide, and medroxyprogesterone acetate may suppress testosterone levels more effectively than spironolactone. However, because spironolactone blocks the androgen receptor directly, it remains unclear whether its lower testosterone suppression translates to meaningfully different feminization outcomes.¹⁴ Research on metabolic biomarkers has found that six months of gender-affirming hormone therapy with either antiandrogen group produces a decrease in blood markers associated with cardiovascular risk, with cyproterone acetate having a somewhat more pronounced effect on lipoprotein levels.¹⁵

Pediatric Endocrine Conditions

Antiandrogens also appear in more specialized endocrine contexts. In an open, randomized, controlled trial, children with classic congenital adrenal hyperplasia were given a combination of an antiandrogen, an aromatase inhibitor, and a reduced dose of hydrocortisone to manage androgen excess while minimizing steroid exposure.¹⁶ These niche uses remind us that androgen receptor blockers are not a one-disease class; they surface wherever androgen activity needs to be dialed down.

Side Effects Across Organ Systems

The side effect profile of antiandrogens reflects the wide reach of androgen signaling itself. Because androgen receptors exist in the heart, brain, liver, bones, and reproductive organs, blocking them can produce consequences far beyond the intended target.

Cardiovascular Risk

Androgen receptor antagonists are linked to increased risk of dangerous heart-rhythm abnormalities, including long QT syndrome and, in rare cases, sudden cardiac death.¹⁷ The risk compounds when drugs are stacked: when androgen receptor signaling inhibitors are added on top of standard androgen deprivation therapy, the risk of a cardiac event roughly doubles. Giving two signaling inhibitors together, such as abiraterone plus enzalutamide, has been associated with an approximately fourfold increase in cardiac risk, with severe events requiring hospitalization occurring in roughly 8% to 16% of patients depending on the disease state.¹⁷

Liver Toxicity

Among first-generation nonsteroidal antiandrogens, flutamide has the most documented record of liver injury. Mild, transient enzyme elevations are common, occurring in over 40% of patients in some series, though they usually normalize over time. In a large study of over 1,000 patients, only about 0.36% developed severe enzyme elevations at four times the upper normal limit or more, and only 0.18% developed clinical signs of liver disease. All resolved after stopping the drug, with no lasting damage on long-term follow-up.¹⁸ Bicalutamide shows a similar but somewhat lower rate of abnormal liver enzymes compared with flutamide.¹⁹ Cyproterone acetate can also cause liver injury, typically with a longer lag time before symptoms appear, and there have been occasional reports of hepatocellular carcinoma and liver cirrhosis attributed to it. Regular liver function tests remain the standard recommendation for anyone on these drugs.²⁰

Bone Loss

Androgens help maintain bone density, and blocking them accelerates bone turnover. Androgen deprivation therapy by any method decreases bone mineral density and increases fracture risk.²¹ A longitudinal study measured bone microarchitecture directly and found a roughly 4% decline in volumetric bone mineral density at 12 months in men on androgen deprivation therapy, compared with less than half a percent decline in untreated controls.²² Randomized trials have shown that treatments like bisphosphonates and denosumab can counteract this bone loss.²³

Sexual, Endocrine, and Body Composition Effects

Loss of libido, erectile dysfunction, hot flashes, fatigue, reduced testicle size, and anemia are among the most commonly reported adverse effects of androgen deprivation therapy overall.²³ Gynecomastia, the growth of breast tissue in men, is particularly associated with antiandrogens used as monotherapy. It is considered the most bothersome side effect by many patients and can become severe enough to cause serious physical and psychological distress. In some cases it does not fully reverse after stopping the drug, likely due to breast tissue fibrosis.²⁴ Prophylactic breast irradiation or tamoxifen are used to prevent or reduce gynecomastia in men who need long-term antiandrogen treatment.²³

Metabolic shifts are another consequence. Weight gain, loss of muscle mass, and increased insulin resistance are well documented with androgen deprivation therapy. Interestingly, the metabolic picture is different in women with hyperandrogenism: in that setting, antiandrogen treatment partially reverses insulin resistance, improving how the body handles glucose regardless of which specific antiandrogen is used.²⁵ The metabolic impact of these drugs, in other words, depends heavily on who is taking them and why.

Cognitive and Mood Changes

Some studies have linked anti-androgen drugs to reduced cognitive function, mood changes, diminished quality of life, and possible associations with dementia and Alzheimer’s disease.²⁶ Not all antiandrogens affect the brain equally. A randomized crossover trial in healthy volunteers found that enzalutamide reduced brain blood flow by about 3.5% globally and by more than 5% in specific brain regions compared with placebo. Darolutamide, a newer second-generation antiandrogen designed not to cross the blood-brain barrier as readily, showed no meaningful change in brain blood flow compared with placebo.²⁷ This is one reason why the choice of antiandrogen, not just whether to use one, can matter for quality of life.

Managing Side Effects and Preserving Quality of Life

The cumulative side-effect burden of antiandrogens is a genuine clinical challenge, and patients routinely report that these effects erode their quality of life.²⁸ When newer signaling inhibitors are added on top of standard androgen deprivation therapy, they tend to worsen existing side effects or introduce new ones.²⁹ Randomized trials have identified several interventions that help: resistance and aerobic exercise to preserve muscle mass and reduce fatigue, venlafaxine or gabapentin for hot flashes, metformin or dietary changes for metabolic shifts, and bone-protective agents for osteoporosis.²³ Early recognition is the practical takeaway: knowing which side effects a specific antiandrogen is most likely to cause means monitoring can start before the problem becomes entrenched.

When These Drugs Stop Working

In prostate cancer, almost all patients eventually develop resistance to antiandrogen therapy. One well-studied escape route involves a shortened version of the androgen receptor called AR-V7. This variant is missing the section of the receptor where enzalutamide and abiraterone bind, yet it remains permanently switched on as a growth signal, allowing the cancer to keep growing without any androgen at all.³⁰ Detecting AR-V7 in circulating tumor cells has become a practical biomarker: its presence signals that switching to a different antiandrogen is unlikely to help, because the cancer’s growth no longer depends on the drug target at all.³¹

This resistance problem has driven the search for entirely new approaches. The most promising is the PROTAC strategy, short for proteolysis-targeting chimera. Instead of just blocking the receptor, PROTACs hijack the cell’s own protein-disposal system to physically destroy the androgen receptor protein. An optimized PROTAC molecule called ARD-61 has been shown to degrade the androgen receptor in cell lines that are resistant to enzalutamide and even in cells overexpressing the AR-V7 splice variant that lacks the drug binding site. In laboratory and animal models, enzalutamide-sensitive and enzalutamide-resistant cells responded equally well to ARD-61.³² Several PROTAC-based androgen receptor degraders are now in various stages of development heading toward clinical trials.³³

Topical Antiandrogens and the Push to Avoid Systemic Exposure

One way to get the benefits of androgen receptor blockade while dodging the systemic side effects is to deliver the drug through the skin, right where it is needed. Clascoterone, a topical antiandrogen cream approved for acne, demonstrates minimal systemic absorption and low plasma concentrations, keeping the drug’s action largely confined to the skin.³⁴ Experimental formulations have gone further: liposomal delivery of the antiandrogen RU 58841 was shown to reduce percutaneous absorption compared with a standard solution, increase drug retention in the dermis, and concentrate the active compound specifically in sebaceous glands, the structures most relevant to acne and androgenic hair loss.³⁵

Topical approaches are unlikely to replace systemic therapy for prostate cancer, where the drug needs to reach tumors throughout the body. But for skin and hair conditions, the ability to block androgen receptors in just the right tissue, without flooding the bloodstream and triggering fatigue, breast tenderness, or metabolic changes, represents a meaningful practical advantage. As formulation science improves, the gap between what topical antiandrogens can do and what oral antiandrogens are used for will continue to narrow for dermatological indications.

Eighty Years of Androgen Targeting and Where It Stands Now

The story of androgen receptor blockers stretches back to 1941, when Huggins and Hodges demonstrated that prostate tumors were sensitive to the presence or absence of androgenic hormones.³⁶ The first hormonal therapy for prostate cancer was surgical castration. Every advance since, from cyproterone acetate to enzalutamide to the PROTAC degraders now in development, has been an attempt to accomplish something similar with drugs rather than surgery, and to do so more precisely. The recurring theme has been that the androgen receptor finds ways to stay active despite every new drug thrown at it, and the field responds by designing yet another approach.³⁷ Meanwhile, the drugs developed along the way have turned out to be useful for conditions no one was thinking about in 1941, from hair loss to gender-affirming care to childhood endocrine disorders, giving androgen receptor blockers one of the wider therapeutic footprints of any drug class in modern medicine.

1
PubMed. Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor
2
PubMed. Mechanisms of action of androgens and antiandrogens: effects of antiandrogens on translocation of cytoplasmic androgen receptor and nuclear abundance of dihydrotestosterone
3
PubMed. Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications
4
Endocrine-Related Cancer. Targeting androgen receptor signaling: a historical perspective
5
Frontiers in Oncology. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
6
PubMed Central. Androgen receptor antagonists in castration-resistant prostate cancer
7
PubMed. GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer
8
PubMed. GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401
9
PubMed Central. Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL
10
PubMed Central. The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis
11
PubMed. Treatment of female pattern hair loss with oral antiandrogens
12
The Lancet. Efficacy and safety of anti-androgens in the management of hormonal and clinical features of polycystic ovary syndrome: a systematic review and meta-analysis
13
PubMed Central. Quality of Life in Polycystic Ovary Syndrome after Anti-Androgen Therapy using PCOSQOL-47 and PCOSQOL-42
14
PubMed. A systematic review of antiandrogens and feminization in transgender women
15
The Journal of Clinical Endocrinology & Metabolism. Impact of Distinct Antiandrogen Exposures on the Plasma Metabolome in Feminizing Gender-affirming Hormone Therapy
16
PubMed Central. Adult Height Following Prepubertal Treatment With Antiandrogen, Aromatase Inhibitor, and Reduced Hydrocortisone in CAH
17
PubMed Central. Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice
18
The American Journal of Medicine. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients
19
PubMed Central. Bicalutamide-induced hepatotoxicity: A rare adverse effect
20
Urologia Internationalis. Hepatotoxicity Induced by Antiandrogens: A Review of the Literature
21
PubMed. Osteoporosis during androgen deprivation therapy for prostate cancer
22
Journal of Bone Oncology. The impact of androgen deprivation therapy on bone microarchitecture in men with prostate cancer: A longitudinal observational study (The ANTELOPE Study)
23
PubMed. Adverse effects of androgen deprivation therapy and strategies to mitigate them
24
PubMed Central. Severe gynecomastia due to anti androgens intake: A case report and literature review
25
PubMed. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women
26
PubMed Central. Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood
27
PubMed Central. Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial
28
PubMed Central. Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues
29
PubMed Central. How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?
30
PubMed Central. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
31
PubMed. Androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer: Molecular mechanisms and therapeutic strategies
32
Cancer Research. Abstract 5679: Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
33
PubMed. Targeting androgen receptor degradation with PROTACs from bench to bedside
34
JEADV Clinical Practice. Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
35
International Journal of Pharmaceutics. Percutaneous absorption of a new antiandrogen included in liposomes or in solution
36
PubMed Central. Eighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
37
Nature Reviews Clinical Oncology. Evolution of androgen receptor targeted therapy for advanced prostate cancer